Have a say: What is your preferred way to receive policy relevant information?
In this short questionnaire we aim to identify the most suitable ways to transfer policy relevant information – the questionnaire is open until 20th March 2026.
In this short questionnaire we aim to identify the most suitable ways to transfer policy relevant information – the questionnaire is open until 20th March 2026.
The MACRAMÉ FInal Dissemination Event (ONLINE) will take place 6th May 2026 10:00 – 15:00 CEST – safe the date!
Epithelix (www.epithelix.com) is a pioneering biotechnology company specialized in tissue engineering and in vitro respiratory disease modelling.
With the expertise brought together in MACRAMÉ and the experiences gained throughout the project duration, MACRAMÉ responded to the call for evidence to the Advanced Materials Act.
In 2025, MACRAMÉ Partners presented key results in posters and talks and attended panel discussions at various events.
MACRAMÉ colleagues from EMPA contributed to the publication ‘Boron Nitride Nanomaterials Trigger Immunomodulatory Effects in Human Broncho-Epithelial Cells by Modulating Eicosanoid Lipid Signaling’. For the successful commercial development of emerging 2D materials, it is crucial to understand their potential biological effects on healthy and diseased individuals.
The ‘Joint Risk Assessor Summit on Advancing Safety & Sustainability Assessments of Advanced Materials’ hosted at the Organisation for Economic Cooperation and Development (OECD) in Paris and co-organised by four Horizon Europe projects ACCORDs, iCARE, MACRAMÉ, and nanoPASS, was a full success. Now, the full report of the event is available.
The Horizon Europe projects MACRAMÉ, iCARE, nanoPASS and DESIDERATA jointly organised an exclusive two-day virtual workshop advancing the harmonization and standardization of testing methodologies for nanomaterials and advanced materials.
MACRAMÉ Experts used the opportunity to provide feedback in the commenting phase of the revision of the Safe and Sustainable by Design Chemicals and Materials Framework.
The development of new approach methodologies (NAMs) to replace current in vivo testing for the safety assessment of engineered nanomaterials (ENMs) is hindered by the scarcity of validated experimental data for many ENMs. MACRAMÉ partners contributed to the publication ‘Wisdom of Crowds for Supporting the Safety Evaluation of Nanomaterials’.